Amarin soars on triglyceride-drug hopes
April 18, 2011 at 14:31 PM EDT
Shares of Amarin rally more than 90% after the release of better-than-expected study data for the company’s cardiovascular-disease drug AMR101.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.